Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/232527CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS IMMUNOGENIC COMPOSITIONS
WO 26.11.2020
Int.Class C12N 15/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
Appl.No PCT/CA2019/051592 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
The present disclosure relates to DNA vaccines against Crimean-Congo Hemorrhagic Fever (CCHF) virus. The present disclosure also relates to CCHF virus sequences and their use for vaccination such as DNA vaccination. The present disclosure more particularly relates to artificial nucleic acid molecules that are able to encode a CCHF polypeptide of an infectious CCHF virus, a fragment or a variant thereof. The nucleic acid molecules of the present application are formulated as immunogenic compositions.
2.WO/2020/234417BLOOD PLATELET PRESERVING COMPOSITION
WO 26.11.2020
Int.Class A01N 1/02
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
1Preservation of bodies of humans or animals, or parts thereof
02Preservation of living parts
Appl.No PCT/EP2020/064196 Applicant MACO PHARMA Inventor HAVET, Coralie
The invention relates to a composition for preserving platelets, comprising an additive solution containing (a) sodium chloride and (b) an acetate compound or a citrate compound or a combination thereof, and a red blood cell aggregation agent chosen from dextran having a molecular weight of 50 kDa or more, polyvinylpyrrolidone having a molecular weight of 40 kDa or more and polyethylene glycol having a molecular weight of 20 kDa or more, or a combination thereof.
3.WO/2020/234547NOVEL BACTERIOPHAGE STRAINS AND USES THEREOF
WO 26.11.2020
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/FR2020/050848 Applicant VETOPHAGE Inventor CHATAIN-LY, Mai Huong
The present invention relates to a composition comprising a bacteriophage strain or a mixture of bacteriophage strains selected from strains such as those stored at the CNCM under numbers CNCM I-5409, CNCM I-5410, CNCM I-5491 and CNCM I-5492. The invention also relates to the therapeutic use of said strains in humans and animals to treat S. aureus infections, in particular for treating mastitis in animals.
4.WO/2020/236777REPROGRAMMING OF LIPID METABOLISM TO INHIBIT T CELL SENESCENCE AND ENHANCE TUMOR IMMUNOTHERAPY
WO 26.11.2020
Int.Class A61P 37/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
04Immunostimulants
Appl.No PCT/US2020/033530 Applicant SAINT LOUIS UNIVERSITY Inventor PENG, Guangyong
The present disclosure provides compositions and methods for inhibiting T cell senescence and improving T cell immunotherapies. In particular, inhibitors of group IV A phospholipase A2 are disclosed as useful in modulating the lipid metabolism of cells, in particular effector T cells, such that T reg- and tumor cell-induced cell senescence is abrogated. These methods may be employed with particular utility in adoptive T cell therapies and/or enhanced T cell effector functions in vivo, including those performed in combination with checkpoint blockade therapies.
5.WO/2020/233776MIC THERAPY FOR SPECIFIC IMMUNOSUPPRESSION IN TRANSPLANTATION
WO 26.11.2020
Int.Class A61K 35/15
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
Appl.No PCT/EP2019/062857 Applicant TOLEROGENIXX GMBH Inventor MORATH, Christian
The present invention relates to pharmaceutical compositions with isolated and treated whole blood cells or Peripheral Blood Mononuclear Cells (PBMCs) as well as such pharmaceutical compositions for use in the prevention and / or treatment of organ or cell graft rejection in a human graft recipient.
6.WO/2020/235936ASYMMETRIC SIRNA INHIBITING EXPRESSION OF PD-1
WO 26.11.2020
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/KR2020/006610 Applicant OLIX PHARMACEUTICALS, INC. Inventor LEE, Dong Ki
The present invention relates to an asymmetric siRNA that inhibits the expression of programmed cell death protein 1 (PD-1), and a use thereof, and more specifically, to: an asymmetric siRNA comprising an antisense strand including a sequence complementary to mRNA encoding PD-1, and a sense strand forming a complementary bond with the antisense strand; a pharmaceutical composition which is for preventing or treating cancer and comprises the asymmetric siRNA; an immune cell which is obtained by treating with the siRNA, and in which the expression of PD-1 is inhibited; and an immune cell therapeutic agent which is for treating cancer and includes the immune cell.
7.WO/2020/236696INHIBITORY INTERNEURON TREATMENT METHODS, USES AND COMPOSITIONS FOR DIABETES
WO 26.11.2020
Int.Class A61K 35/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
Appl.No PCT/US2020/033368 Applicant DIGNITY HEALTH Inventor MIRZADEH, Zaman
Disclosed herein are compositions, methods of treatment, and uses of inhibitory interneuron precursors, derived from the brain's medial ganglionic eminence, or differentiated from iPSC or ESCs, for the treatment of pre-diabetes or diabetes. In some embodiments, compositions including inhibitory interneuron precursors are transplanted into the arcuate nucleus of the hypothalamus region of the brain, to treat, for example, diabetes, such as, type-2 diabetes, In further embodiments, inhibitory interneuron precursors are used in the manufacture of a medicament for the treatment of diabetes, for example, type-2 diabetes.
8.WO/2020/237006METHOD OF COSMETIC PRESERVATION
WO 26.11.2020
Int.Class A61K 35/741
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
Appl.No PCT/US2020/033922 Applicant AHERN, Mary Inventor AHERN, Mary
Provided is a method for making a composition for application to skin with improved antimicrobial properties. The method of making a composition for application to skin includes: combining a raw material, water, and a first agent in a first amount effective to inhibit microbial growth to obtain a first mixture; and mixing a second agent in a second amount effective to inhibit microbial growth and the first mixture to obtain a second mixture, wherein a temperature of the second agent is maintained at equal to or less than about 33°C. A composition for application to skin is also provided. The composition for application to skin includes a first agent in a first amount effective to inhibit microbial growth and a second agent in a second amount effective to inhibit microbial growth. The first agent may include a fermentate. The second agent may include a probiotic. The composition for application to skin may further include at least one essential oil and/or at least one terpene.
9.WO/2020/237216METHOD FOR COLD ATMOSPHERIC PLASMA EXOSOME THERAPY
WO 26.11.2020
Int.Class A61K 35/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Appl.No PCT/US2020/034388 Applicant JEROME CANADY RESEARCH INSTITUTE FOR ADVANCED BIOLOGICAL AND TECHNOLOGICAL SCIENCES Inventor CANADY, Jerome, M.D.
A method for bioengineering exosomes for cancer treatment. The method comprises the steps of isolating target tumor cells from a tissue sample, culturing the isolated target tumor cells, treating the cultured target tumor cells with cold atmospheric plasma to release exosomes from the target tumor cells, and collecting the released exosomes. The step of culturing the target tumor cells may comprise seeding the isolated target tumor cells in wells and incubating the target tumor cells in a culture media, for example, for 24 hours. The culture media may comprise Dulbecco's Modified Eagle Medium, an antibiotic and 10% fetal bovine serum. The step of culturing the target tumor cells may further comprise replacing the culture media with Dulbecco's Modified Eagle Medium and an antibiotic. The target tumor cells may comprise, for example, one of U87 cells, KKU-055 cells and triple negative MDA-MB-231 cells.
10.WO/2020/234035USE OF POLYGLYCEROL ESTERS ALS AS CARRIERS FOR MICROBIOLOGICAL ACTIVE INGREDIENTS
WO 26.11.2020
Int.Class A01N 25/30
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
25Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
30characterised by the surfactants
Appl.No PCT/EP2020/063123 Applicant EVONIK OPERATIONS GMBH Inventor HÄNSEL, René
The invention relates to: the use of compositions comprising at least one polyglycerol ester and preferably at least one emulsifier, as carriers for a microbiological active ingredient; to compositions comprising both the carriers and also the microbiological active ingredient; to a method for increasing the storage stability of the microbiological active ingredient; and to the use of said compositions for treating plants, for treating seed, for treating soil, as a biostimulant, as a probiotic food supplement, or probiotic animal foodstuff additive.